The Anti-fibrotic Therapeutic Effects of Resveratrol for Discharged COVID-19 Patients

Unknown 30 enrolled Hong Kong Baptist University Hospital Authority, Hong Kong · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

A randomized controlled trial (RCT) will be conducted to evaluate the anti-fibrotic therapeutic effects of resveratrol on the clinical symptoms in discharged COVID-19 patients.

Timeline

Start: 2021-04-01
Primary completion: 2022-05
Completion: 2022-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Resveratrol	Small molecule	1 g	Oral

The Anti-fibrotic Therapeutic Effects of Resveratrol for Discharged COVID-19 Patients

Summary

Timeline

Drugs

Indications